Individual and cumulative effects of GWAS susceptibility loci in lung cancer: Associations after sub-phenotyping for COPD

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Young, Robert P ^a,c   Hopkins, Raewyn J ^a   Whittington, Chris F ^a   Hay, Bryan A ^a   Epton, Michael J ^b   Gamble, Gregory D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Synergenz Biosciences Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENE LOCUS; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ADENOCARCINOMA; CLASSIFICATION; COHORT ANALYSIS; EPIDEMIOLOGY; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; PHYSIOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CAUSALITY; COHORT STUDIES; FEMALE; GENETIC LINKAGE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 79751471246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016476     Document Type: Article

References (85)

1. Broderick P, Wang Y, Vijayakarishnan J, Matakidou A, Spitz MR, et al. (2009) Deciphering the impact of common genetic variation on lung cancer risk: A genome-wide association study. Cancer Res; 69: 6633-6641.
2. Molfino NA (2004) Genetics of COPD. Chest; 125: 1929-1940.
3. Mattson ME, Pollack ES, Cullen JW (1987) What are the odds that smoking will kill you? Am J Pub Health 77: 425-431.
4. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, et al. (2009) The natural history of chronic airflow obstruction revisited: An analysis of the Framingham Offspring Cohort. Am J Respir Crit Care Med 180: 3-10.
5. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J (2006) Developing COPD: A 25 year follow up study of the general population. Thorax 61: 935-939.
6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J (2000) Environmental and heritable factors in the causation of cancer: Analyses of cohorts of twins from Sweden, Denmark and Finland. N Eng J Med 343: 78-85.
7. Redline S, Tishler PV, Rosner B, Lewitter FI, Vandenburgh M, et al. (1989) Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. Am J Epidemiol 129: 827-836.
8. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, et al. (2009) COPD prevalence is increased in lung cancer independence of age, gender and smoking history. Euro Respir J 34: 380-386.
9. Mannino DM, Aguayo SM, Petty TL, Redd SC (2003) Low lung function and incident lung cancer in the United States: Data from the first NHANES followup. Arch Int Med 163: 1475-1480.
10. Burrows B, Knudson RJ, Cline MG, Lebowitz MD (1977) Qualitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 115: 195-205.
11. Dockery DW, Speizer FE, Ferris BG, Jr., Ware JH, Louis TA, et al. (1988) Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis 137: 286-292.
12. Young RP, Hopkins RJ, Eaton TE (2007) Forced expiratory volume in one second: Not just a lung function test but a marker of premature death from all causes. Eur Respir J 30(4): 616-622.
13. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, et al. (2008) Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 178: 738-744.
14. de Torres J, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, et al. (2007) Assessing the relationship between lung cancer risk and emphysema detected on low dose CT of the chest. Chest 132: 1932-1938.
15. Mortensen EM, Copeland LA, Pugh MJ, Fine MJ, Nakashima B, et al. (2010) Diagnosis of pulmonary malignancy after hospitalisation for pneumonia. Am J Med 123: 66-71.
16. Wilk JB, Walter RE, Laramie JM, Gottlieb DJ, O'Connor GT (2007) Framingham heart study genome-wide association: Results for pulmonary function measures. BMC Med Genet 8(S1): S8.
17. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genetics 40: 616-622.
18. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637.
19. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642.
20. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, et al. (2009) A genome-wide association study in chronic obstructive pulmonary disease (COPD): Identification of two major susceptibility loci. PLoS Genetics 5: 1-8.
21. Wilk JB, Chen T, Gottlieb DJ, Walter RE, Nagle MW, et al. (2009) A genomewide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genetics 5(3): e1000429.
22. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, et al. (2009) Genome-wide association study identifies five loci associated with lung function. Nature Genetics 42: 36-44.
23. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, et al. (2009) Metaanalyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nature Genetics 42: 45-52.
24. Petty TL (2005) Are COPD and lung cancer two manifestations of the same disease? Chest 128: 1895-1897.
25. Schwartz AG, Ruckdeschel JC (2006) Familial lung cancer: Genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173: 16-22.
26. Young RP, Hopkins RJ, Hay BA, Epton MJ, Black PN, et al. (2008) Lung cancer gene associated with COPD: Triple whammy or possible confounding effect? Eur Respir J 32: 1-7.
27. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, et al. (2009) Lung cancer susceptibility model based on age, family history and genetic variants. Plos One 4: e5302.
28. Young RP, Whittington CF, Hopkins RJ, Hay BA, Epton MJ, et al. (2010) Chromosome 4q31 locus in COPD also associated with lung cancer. Eur Respir J 36: 1375-1382.
29. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM (2009) Lung cancer and chronic obstructive pulmonary disease: Needs and opportunities for integrated research. JNCI 101: 554-559.
30. Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Reviews Genet 8: 657-662.
31. Janssens ACJW, van Duijn CM (2009) Genome-based prediction of common disease: methodological considerations for future research. Genome Med 1: 20.
32. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, et al. (2009) A gene based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J 85: 515-524.
33. Stav D, Raz M (2007) Prevalence of chronic obstructive pulmonary disease among smokers aged 45 and up in Israel. Isr Med Assoc J 9: 800-802.
34. Yang P, Yafei L, Jiang R, Cunningham JM, Zhang F, et al. (2010) A rigorous and comprehensive validation: Common genetic variations and lung cancer. Cancer Epidemiol Bio Prev 19: 240-244.
35. Lambrechts D, Buysschaert I, Zanen P, Coolen J, Lays N, et al. (2010) The 15q24/25 susceptibility variant for lung cancer and COPD is associated with emphysema. Am J Resipr Crit Care Med 181: 486-493.
36. Moskvina V, Holmans P, Schmidt KM, Craddock N (2005) Design of casecontrols studies with unscreened controls. Ann Hum Genet 68: 566-576.
37. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, et al. (2008) Cumulative association of five genetic variants with prostate cancer. NEJM 358: 910-919.
38. Easton DF, Peto J, Babiker AGAG (1991) Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Statistics in Medicine 10: 1025-1035.
39. Plummer M (2004) Improved estimates of floating absolute risk. Statistics in Medicine 23: 93-104.
40. Pritchard J, Stephens M, Donnelly P (2000) Inference of population structure from multilocus genotype data. Genetics 155: 945-959.
41. Thankkinstian A, Thompson JR, Minelli C, Attia J (2009) Choosing between per-genotype, per-allele, and trend approaches for initial detection of genedisease association. J App Stat 36(6): 633-646.
42. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, et al. (2005) Clinical Features of 5,628 Primary Lung Cancer Patients: Experience at Mayo Clinic from 1997 to 2003. Chest 128: 452-462.
43. Jin G, Xu L, Shu Y, Tian T, Liang J, et al. (2009) Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis 30: 987-990.
44. Young RP, Hopkins R, Eaton TE (2009) Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 18: 222-232.
45. Brown V, Elborn JS, Bradley J, Ennis M (2009) Dysregulated apoptosis and NFKB expression in COPD subjects. Resp Research 10: 24.
46. Sohal SS, Reid D, Soltani A, Ward C, Weston S, et al. (2009) Smoking has potential to initiate basement membrane disruption and epithelial mesenchymal transition in COPD. Abstract #1603 Vienna: European Respiratory Society Meeting.
47. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N (2006) Epithelialmesenchymal transition in lung cancer: Is tobacco the "smoking gun"? Am J Respir Cell Mol Biol 35: 3-9.
48. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X (2003) Genetic susceptibility to lung cancer: The role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 12: 689-697.
49. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ (2008) Collagen 1 promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-b signalling. Am J Respir Cell Mol Biol 38: 95-104.
50. Zondag GCM, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, et al. (2000) Oncogenic Ras downregulates rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 149: 775-782.
51. Lee G, Walser TC, Dubinett SM (2009) Chronic inflammation, chronic obstructive pulmonary disease and lung cancer. Curr Opin Pulm Med 15: 303-307.
52. Weiss KM, Clark AG (2002) Linkage disequilibrium and the mapping of complex human traits. Trends Genet 18: 19-24.
53. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB (2010) Rare variants create synthetic genome-wide associations. PLoS Biol 8: e1000294.
54. Gwilt CR, Donnelly LE, Rogers DF (2007) The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation? Pharmacol Therapeut 115: 208-222.
55. Schuller HM (2007) Nitrosamines as nicotinic receptor ligands. Life Sci 80: 2274-2280.
56. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, et al. (2008) Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 165: 1163-1171.
57. Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, et al. (2006) Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 16: 693-701.
58. Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, et al. (2007) HLA-Bassociated transcript 3 (BAT3)/Scythe is essential for p300-mediated acetylation of p53. Genes and Development 21: 848-861.
59. Shi W, Chen F, Cardoso WV (2009) Mechanisms of lung development: Contribution to adult lung disease and relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 6: 558-563.
60. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, et al. (2003) Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422: 313-317.
61. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ (2008) Collagen I promotes epithelial-to-Mesenchymal Transition in lung cancer cells via transforming growth factor- signalling. Am J Respir Cell Mol Biol 38: 95-104.
62. Minetti M, Leto TL, Malorni W (2008) Radical generation and alterations of erythrocyte integrity as bio-indicators of diagnostic or prognostic value in COPD? Antioxidants & Redox Signaling 10: 829-839.
63. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, et al. (2010) Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nature Genetics 42: 200-202.
64. Young RP, Hopkins RJ, Hay BA, Whittington CF, Epton MJ, et al. (2011) FAM13A locus in COPD independently associated with lung cancer - evidence of a molecular genetic link between COPD and lung cancer. App Clin Genet 4: 1-10.
65. Arribas J, Bech-Serra JJ, Santiago-Josefat B (2006) ADAMs, cell migration and cancer. Cancer Metastasis Rev 25: 57-68.
66. Dijkstra A, Postma DS, Noordhoek JA, Ladewijk ME, Kauffman HF, et al. (2009) Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch 454: 441-449.
67. Qi B, Newcomer RG, Sang QXA (2009) ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases. Current Pharmaceutical Design 15: 2336-2348.
68. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson S, et al. (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nature Genetics 41: 221-227.
69. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, et al. (2006) Genetic variation is associated with C-reactive protein levels in the third national health and nutrition examination survey. Circulation 114: 2458-2465.
70. Rasmussen F, Mikkelsen D, Hancox RJ, Lambrechtsen J, Nybo M, et al. (2009) High-sensitive C-reactive protein is associated with reduced lung function in young adults. Euro Respir J 33: 382-388.
71. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27: 2217-2224.
72. Hofmann MA, Dury S, Hudson BI, Gleason MR, Qu W, et al. (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3: 123-135.
73. Ferhani N, Letuve S, Kozhich A, Thibaudeau D, Grandsaigne M, et al. (2010) Expression of High-Mobility Group Box 1 and of Receptor for Advanced Glycation End products in Chronic Obstructive Pulmonary Disease. Am J Resipr Crit Care Med 181: 917-927.
74. Bartling B, Hofmann HS, Weigle B, Silber R-E, Simm A (2005) Downregulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301.
75. Weinshilboum R (2003) Inheritance and drug response. N Eng J Med 348: 529-537.
76. Tockman MS, Anthonisen NR, Wright EC, Donithan MG, et al. (1987) Airways obstruction and the risk for lung cancer. Annal Int Med 106: 512-518.
77. Anthonisen NR, Connett JE, Enright PL, Manfreda J, et al. (2002) Hospitalizations and mortality in the Lung Health Study. Am J Resipr Crit Care Med 166: 333-339.
78. Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, et al. (2009) Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 34: 812-818.
79. Piitulainen E, Eriksson S (1999) Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J 13: 247-251.
80. Wright CF, Kroese M (2010) Evaluation of genetic tests for susceptibility to complex diseases: why, when and how? Hum Genet 127: 125-134.
81. You M, Wang D, Liu P, Vikis H, James M, et al. (2009) Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 15: 2666-2674.
82. Wald NJ, Hackshaw AK (1999) When can a risk factor be used as a worthwhile screening test? Brit Med J 319: 1562-1565.
83. Xu H, Spitz MR, Amos CI, Shete S (2005) Complex segregation analysis reveals a multigene model for lung cancer. Hum Genet 116: 121-127.
84. Shields P, Harris C (2000) Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18: 2309-2315.
85. Pearson TA, Manolio TA (2008) How to interpret a genome-wide association study. JAMA 299: 1335-1344.